Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting

Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting

Abstract Chimeric antigen receptors (CAR) are engineered fusion proteins that target T-cells to specific surface antigens of tumor cells to generate effective anti-tumor responses. CAR T-cell therapy is playing an increasingly important role in the treatment of relapsed/refractory B-cell malignancie...

Full description

Bibliographic Details
Main Authors: Wenjie Zhang, Sumei Li, Jinlan Long, Shufeng Xie, Minghui Wang, Han Liu, Zhenshu Xu
Format: Article
Language:English
Published: BMC 2024-04-01
Series:Experimental Hematology & Oncology
Subjects:
CAR T-cell therapy
Relapsed/refractory B-cell malignancies
ASH 2023
Online Access:https://doi.org/10.1186/s40164-024-00508-4

Internet

https://doi.org/10.1186/s40164-024-00508-4

Similar Items